Back to News
Market Impact: 0.2
Teva's immune disorder drug meets main goal in mid-stage trial
Source: reuters.com
Healthcare & BiotechCompany Fundamentals
Teva said its experimental drug met the primary goal in a mid-stage trial by helping prevent gluten-related intestinal damage in adults with celiac disease. The update is an early clinical efficacy milestone, but no magnitude (e.g., effect size or interim safety details) was provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
TEVA0.45
More News
- Palantir patient data tech rejected by many NHS trusts in England
- Why did CoreWeave stock get crushed this week? Look to this corner of the debt market for clues
- Diageo's Toxic Spill Hits Pristine River in Scottish Whisky Country
- AI stock sell-off ramps up over debt-fueled data center spending fears: ‘Full-blown crisis of confidence'
- Apple’s $1,999 iPhone Duo puts the company's status-symbol power to the test
- Yields continue to rattle investors. These sectors are most at risk if rates stay elevated